Please login to the form below

The role of medical affairs in positive and appropriate engagement with patient advocacy groups

Written by Gavin Jones, Dr Alexandra Safronova & Professor Peter Rutherford, OPEN Health

Following a series of workshops at a recent Medical Affairs Professionals Society (MAPS) Congress in Amsterdam, workshop leaders Gavin Jones, Dr Alexandra Safronova and Professor Peter Rutherford share their lessons learnt on how medical affairs departments within pharmaceutical companies can help create better partnerships with patient advocacy groups

Pink divider

Patient advocacy groups continue to mobilise and play an increasingly important role in delivering advice and support helping to get treatments to those most in need by Influencing many elements of drug development and patient access processes. This is very much the case in rare disease where groups give critical support to patients and those close to them through influential programmes delivered  with passion and dogged persistence.

Biopharma recognises the importance of positive engagement and partnership with patient groups. Gaining a far greater understanding of the patient journey helps to translate innovations into actual benefits for patients and caregivers in improved clinical outcomes and patient experience.

A question remains around how, and which part of a biopharma organisation should be involved in building patient group relationships. Many organisations invest in patient advocacy leads to support engagement, but they are often brought in to support dialogue as new treatment is becoming available.  As   patient  groups  are  rightly  getting involved in activities much earlier in the drug development process who should lead engagement at this stage and support over the longer term?

This was a question that was posed at workshops during the recent Medical Affairs Professionals (MAPS) meeting in Europe. MAPS is an organisation that supports the sharing of best practice amongst leaders in this key function of pharmaceutical companies. So, who are medical affairs and what is their role?

Read the full article here:

Pink divider

Get in touch

For more information on rare disease contact:

Gavin Jones, Director of Rare Disease, OPEN Health

30th January 2020


Company Details

OPEN Health

+44 1628 481112

Contact Website

The Weighbridge
Brewery Courtyard
High Street
United Kingdom

Latest content on this profile

Rare Disease Day 2021
To mark Rare Disease Day 2021 on Sunday 28 February, OPEN Health will be intentionally quiet on all LinkedIn channels from 26 February to 1 March in order not to distract from awareness generated by patient groups.
OPEN Health
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health

OPEN Health
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health

OPEN Health
OPEN Health Group Appoints New Leadership

OPEN Health
OPEN VIE and Pharmerit Bring the Best of Both Worlds to Virtual ISPOR Europe 2020
Join OPEN VIE and Pharmerit – an OPEN Health Company at the ISPOR European Virtual Conference from 16-19 November 2020 to see how we are shaping the healthcare industry with innovative research methods and world-class communications.
OPEN Health
OPEN Health brings the Best of Both Worlds to MAPS EMEA 2020

OPEN Health